Rocbrutinib Plus Chemotherapy for Resistant B-Cell Lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests whether combining a new drug called rocbrutinib with standard chemotherapy (R-GemOx) works better for patients whose diffuse large B-cell lymphoma (a type of blood cancer) has stopped responding to previous treatments. Researchers hope this combination may help patients who have limited options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your lymphoma must be a specific non-GCB type that has returned or stopped responding to prior treatment
- You must have at least one tumor lesion large enough to measure on scans
- You must be in good enough overall health (ECOG score 0-2) to tolerate the treatment
- You cannot have had a stem cell transplant, CAR-T therapy, or previous BTK inhibitor or R-GemOx treatment
- You must be willing to use effective birth control and cannot be pregnant or nursing
- Your side effects from previous cancer treatments must have mostly resolved
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a targeted therapy called orelabrutinib to standard chemotherapy (R-CHOP) helps people with a specific type of fast-growing lymphoma (CD5-positive DLBCL). If you have this lymphoma and haven't had a BTK inhibitor before, this combination might work better than chemo alone.
This trial tests a new targeted therapy, Rocbrutinib, for a specific type of aggressive B-cell lymphoma (non-GCB DLBCL) that has not responded to or returned after two or more prior treatments. It aims to see if Rocbrutinib can help people who have few other options.
This trial tests a combination of two new drugs (rocbrutinib and lacutoclax) to treat B-cell lymphomas and leukemias. The goal is to see if this combination works better than standard treatments, especially for patients whose cancer has come back or stopped responding to previous therapy.
This trial tests a new targeted therapy (pirtobrutinib) combined with standard chemo-immunotherapy, with or without an extra targeted drug (polatuzumab vedotin), for people whose large B-cell lymphoma has returned or not responded after prior BTK inhibitor treatment. The goal is to see if this combination can help control the cancer.
This trial tests a new drug called pirtobrutinib combined with standard chemotherapy (R-CHOP) for people with a type of large B-cell lymphoma that hasn't been treated before. The goal is to see if adding this drug helps the treatment work better.
This study tests a new targeted therapy called Rocbrutinib against other BTK inhibitors for people with mantle cell lymphoma that has come back or not responded to prior treatment. It aims to see which works better and how safe they are.
Hear when a new DLBCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.